The Oxazolidinones.

Area of Science:

• Pharmacology and Infectious Diseases
• Antimicrobial Resistance
• Clinical Microbiology

Background:

• Increasing frequency of antibiotic-resistant gram-positive infections globally.
• Clinical need for novel therapeutic agents to combat resistant bacterial strains.
• Development of linezolid as the first oxazolidinone antibiotic.

Purpose of the Study:

• To evaluate the efficacy of linezolid against key gram-positive pathogens.
• To assess linezolid's role in treating serious infections caused by resistant bacteria.
• To report on the emergence of linezolid-resistant strains during clinical use.

Main Methods:

• Clinical trials assessing linezolid for skin, soft tissue, and respiratory tract infections.
• Compassionate use program data for vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus infections.
• Monitoring for the emergence of linezolid-resistant gram-positive cocci.

Main Results:

• Linezolid demonstrated bacteriostatic activity against susceptible and resistant staphylococci, enterococci, and streptococci.
• Confirmed effectiveness in treating serious skin, soft tissue, and lower respiratory tract infections.
• Improved outcomes observed in compassionate use for vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus infections.

Conclusions:

• Linezolid is an effective treatment for serious infections caused by antibiotic-resistant gram-positive bacteria.
• Emergence of linezolid resistance has been documented during clinical use.
• Reserve linezolid for treating antibiotic-resistant gram-positive infections to preserve its efficacy.